Related by context. All words. (Click for frequent words.) 85 blind randomized placebo 80 randomized placebo controlled 78 placebo controlled randomized 78 blind randomized controlled 78 placebo controlled 77 double blind placebo 76 prospective randomized 76 randomized double 75 randomized controlled 75 blind multicenter 75 Phase III randomized 75 randomized multicenter 75 blind placebo controlled 75 multicentre 74 multicenter randomized 74 randomized 73 multicenter 72 multicenter randomized placebo controlled 72 masked placebo controlled 71 prospective randomized controlled 71 blinded placebo controlled 70 multicentre randomized double 70 controlled multicenter 70 multicenter randomized double 70 randomized clinical 69 blinded randomized 69 double blinded randomized 69 blind randomized multicenter 69 multicentre randomized 69 dose dose escalation 68 prospective randomized placebo 68 placebo controlled Phase 68 blind placebo 67 randomized multicentre 67 randomized #:# 67 label multicenter 67 placebo controlled Phase III 67 prospective multicenter 66 double blinded placebo 66 randomized controlled trial 66 active comparator 66 randomized blinded 66 randomized Phase III 66 multicenter prospective 66 randomized controlled clinical 66 placebo controlled clinical 66 prospective observational 66 Randomized 66 multicenter placebo controlled 65 dose escalation trial 65 blind multicentre 65 nonrandomized 64 multicenter randomized controlled 64 multicenter study 64 prospective randomized multicenter 64 TMC# C# 64 dose escalation Phase 63 blinded randomized placebo controlled 63 multicenter Phase III 63 dose escalation study 63 label dose escalation 63 RE LY ® 63 Phase 1b clinical 63 multicenter multinational 62 multinational multicenter randomized 62 landmark ATHENA 62 multicenter clinical 62 multicenter Phase II 62 prospective multicenter randomized 62 single ascending dose 62 Phase IIIb 62 placebo controlled dose escalation 62 ascending doses 61 multicenter phase 61 Randomised 61 multicentre study 61 phase IIb 61 Phase 1a 61 nab paclitaxel 60 ascending dose 60 Phase 2b study 60 controlled dose escalation 60 prospective cohort 60 Phase IIb trial 60 pharmacokinetics PK 60 pivotal Phase III 60 placebo controlled studies 60 trials RCTs 60 observer blinded randomized 60 mg BID 60 Sorafenib HCC Assessment 60 multicentre prospective 60 HCV SPRINT 60 safety tolerability pharmacokinetics 59 dose escalation 59 prospectively randomized 59 Phase 2b 59 randomized multicenter trial 59 Placebo controlled 59 Phase IIb 59 dose regimens 59 Multicenter 59 EURIDIS 59 randomized blinded placebo 59 phase IIb clinical 59 ONTARGET 59 subanalysis 59 Phase Ib 59 multicentre randomized controlled 59 phase Ib 59 label multicenter randomized 59 BRIM2 59 Phase 2b clinical 59 sunitinib malate 59 phase IIIb 59 pharmacodynamics 59 ADVANCE PD 59 NO# [002] 58 ROCKET AF 58 prospective nonrandomized 58 RG# ITMN 58 observational study 58 randomized clinical trials 58 Randomized controlled 58 phase IIa clinical 58 phase IIa 58 relapsed MM 58 Phase III clinical 58 randomized placebo 58 randomized controlled Phase 58 LUX Lung 58 RE LY 58 TAXUS ATLAS 58 #mg/day [001] 58 PRE SURGE 58 Phase 1b trial 58 AIR CF1 58 label dose titration 58 HCV RESPOND 2 58 Phase IIa 58 multicenter randomized clinical 58 randomized Phase IIb 58 label multicenter Phase 58 placebo controlled trials 58 symptomatic BPH 58 Phase IIIb clinical 58 randomized Phase 58 clinical trial 57 oral rivaroxaban 57 randomized crossover 57 multiple ascending dose 57 pivotal Phase 57 LEXIVA r 57 blinded randomized controlled 57 dose regimen 57 TG MV 57 viral kinetic 57 Phase 2b trial 57 Phase Ib clinical 57 Phase 2a clinical 57 #:# randomization 57 substudy 57 Phase III placebo controlled 57 Phase III 57 CLL8 57 dose escalation clinical 57 dose cohorts 57 Phase 2b randomized 57 mg administered orally 57 Phase 1b 57 Initiated Phase 57 multicenter Phase 57 dyskinesia PD LID 57 Phase III randomized controlled 57 Randomized Double Blind Placebo 56 dose titration 56 XIENCE V demonstrated 56 pegylated interferon alfa 2b 56 evaluating Vectibix 56 FAME Study 56 ExTRACT TIMI 56 unblinded 56 retrospective cohort 56 PRECiSE 56 AIR CF3 56 randomized controlled multicenter 56 pegylated interferon alfa 2a 56 non inferiority 56 Val HeFT 56 randomized controlled trials 56 ritonavir boosted 56 BRIM3 56 Phase III pivotal 56 treatment naive genotype 56 randomized controlled clinical trials 56 placebo controlled clinical trials 56 tolerability 56 dabigatran etexilate 56 comparing XIENCE V 56 eptifibatide 56 REALITY Trial 56 COMFORT II 56 Phase #/#a 56 Phase III multicenter 56 randomized trials 56 ACTEMRA TM 56 plus ribavirin 56 IFN alfa 56 TMC# r 56 treatment naïve genotype 56 Randomized Phase 55 Randomized Evaluation 55 longitudinal cohort study 55 telaprevir dosing 55 dose placebo controlled 55 irbesartan 55 Carotid Revascularization Endarterectomy vs. 55 AIR CF2 55 safety tolerability pharmacokinetic 55 mg/m2 dose 55 peginterferon alfa 2b 55 monotherapy 55 BCIRG 55 Phase IIIb study 55 Phase IIa trial 55 PRoFESS 55 NSABP B 55 administered subcutaneously 55 placebo controlled multicenter 55 mg dose 55 CALGB 55 mg QD 55 factorial design 55 bolus injection 55 Phase IIb clinical 55 Phase Ia 55 prospectively defined 55 dosage regimens 55 safety tolerability 55 dosing regimens 55 Phase #b/#a 55 post hoc 55 oral deforolimus 55 darunavir ritonavir 55 ABSORB clinical 55 randomized #:#:# 55 evaluating tivozanib 55 #mg QD [002] 55 Pegasys ® 55 CLARITY study 55 EDEMA3 55 lopinavir r 55 GetGoal Phase III 55 relapsed myeloma 54 RECORD1 54 Phase 2a trial 54 noninferiority 54 weekly subcutaneous injections 54 PREZISTA r 54 rosuvastatin 54 REYATAZ r 54 TRITON TIMI 54 Study ADX# 54 Phase Ib II 54 unfractionated heparin UFH 54 pharmacodynamics PD 54 Prostate Lung Colorectal 54 pimecrolimus cream 54 prospective multicentre 54 EVEREST II 54 analgesic efficacy 54 relapsed refractory multiple myeloma 54 BR.# 54 NSTE ACS 54 de novo kidney transplant 54 teriflunomide 54 CHAMPION PCI 54 dosing cohorts 54 recurrent malignant glioma 54 Pivotal Trial 54 zonisamide SR 54 azacitidine 54 DAPT 54 dose escalation phase 54 pharmacodynamic profile 54 confirmatory Phase III 54 Clinical Antipsychotic Trials 54 adjunctive placebo 54 Peg IFN 54 daily Infergen 54 Phase 2a 54 comparator arm 54 APTIVUS 54 multicentric 54 controlled multicenter Phase 54 ritonavir boosted atazanavir 54 RRMS patients 54 peginterferon alfa 2a 54 LPV r 54 RE SURGE 54 n = 54 Phase III VISTA 54 phase III ACCLAIM 54 prospective observational cohort 54 Phase IIb IIIa 54 ENDEAVOR IV 54 thorough QT 54 CAMMS# 54 galiximab 53 sirolimus eluting stent 53 TAXUS V 53 Parkinson disease levodopa induced 53 ACTEMRA 53 ZYBRESTAT fosbretabulin 53 composite endpoint 53 Placebo Controlled 53 daunorubicin 53 BOLDER II 53 cetrorelix 53 diabetic neuropathic pain 53 registrational Phase 53 dosing cohort 53 Multiple Ascending Dose 53 EINSTEIN DVT 53 boosted protease inhibitor 53 HCV infected 53 docetaxel Taxotere R 53 pharmacokinetics 53 EchoCRT 53 Edge STudy 53 Pegasys plus Copegus 53 RG# [001] 53 CANCIDAS 53 relapsed APL 53 metastatic HRPC 53 fosbretabulin 53 TAXUS IV 53 relapsing remitting multiple sclerosis 53 colesevelam HCl 53 PRECISE 53 recurrent glioblastoma multiforme 53 pegylated liposomal doxorubicin 53 APEX PD 53 CRESTOR #mg 53 subcutaneously administered 53 glycoprotein IIb IIIa inhibitor 53 Phase IIa clinical 53 #mg BID [001] 53 phase 2a 53 APTIVUS r 53 NOXAFIL Oral Suspension 53 posaconazole 53 Initiate Phase 53 ECASS 53 carboplatin paclitaxel 53 retrospective observational study 53 melphalan prednisone 53 ascending dose study 53 adalimumab 53 Phase IIb randomized 53 Phase Ib clinical trials 53 RESOLUTE 53 randomly assigned 53 NCCTG 53 Blind Placebo Controlled 53 PFO migraine 53 lacosamide 53 confirmatory clinical 53 null responder HCV 53 IIa clinical 53 investigational oral 53 FOLFOX 53 IV bolus 53 CATIE AD 53 Cardiac Allograft Rejection 53 Multicentre 53 riociguat 53 GEM OS1 53 ASCEND HF 53 ribavirin RBV 53 blinded placebo 53 superficial bladder cancer 53 REVIVE 53 Phase III randomized placebo 53 mcg kg 53 PREVAIL 53 VICTOR E1 53 APPRAISE 53 desvenlafaxine succinate 53 HPTN 53 MIST II 53 intravitreal injection 53 phase IIb study 53 phase IIb trial 53 Phase Ib IIa 53 AIR2 Trial 53 NEVO 53 primary hypercholesterolemia 53 Traficet EN 52 Trandolapril 52 NRTI 52 dose clopidogrel 52 assessing T DM1 52 mcg BID 52 Thrombolysis 52 oral diclofenac 52 rosuvastatin #mg 52 pharmacokinetic PK 52 subcutaneous SC 52 sorafenib Nexavar ® 52 Amrubicin 52 sorafenib Nexavar 52 alfa 2a 52 tolerability pharmacokinetics 52 docetaxel chemotherapy 52 designated HVTN 52 mg RDEA# 52 trastuzumab emtansine T DM1 52 PEGINTRON TM 52 PREZISTA ritonavir 52 Phase 1a clinical 52 OLYMPIA registry 52 telmisartan 52 patients undergoing percutaneous 52 evaluating Xcytrin 52 tolerated dose MTD 52 retrospective cohort study 52 ACTIVE W 52 EQUIP OB 52 pharmacokinetic 52 estramustine 52 subgroup analyzes 52 evaluating REVLIMID 52 paclitaxel eluting stents 52 insulin detemir 52 SPIRIT IV 52 evaluable patients 52 gemcitabine carboplatin 52 bendamustine 52 BARI 2D 52 darunavir r 52 Phase III trials 52 cilostazol 52 anti arrhythmic drug 52 VADT 52 TMC# [001] 52 Randomized Double blind 52 Phase IIb III 52 SPIRIT FIRST 52 candesartan cilexetil 52 LITHE 52 Phase III metastatic melanoma 52 plus dexamethasone 52 Myocardial Infarction Study 52 8mg/kg 52 Prospective Randomized 52 abacavir lamivudine 52 placebo 52 mg TID 52 Denufosol 52 SPIRIT III 52 observational cohort study 52 pharmacodynamic effects 52 eszopiclone 52 afatinib 52 Phase 1b clinical trials 52 oral ridaforolimus 52 RoACTEMRA 52 JANUVIA 52 Val MARC 52 REYATAZ ritonavir 52 dose cohort 52 Stenting Trial CREST 52 fallopian tube cancers 52 OPT CHF 52 tirofiban 52 ABCSG 52 dacarbazine 52 TMC# [002] 52 Folfox 52 registrational trial 52 Trial Evaluating 52 cluster randomized controlled 52 naïve HCV 52 somatostatin analog 52 Cloretazine 52 Navelbine 52 lubiprostone 52 pharmacokinetic PK study 52 viral kinetics 52 MEND CABG 52 NATRECOR ® 52 pharmacokinetic characteristics 52 ENDEAVOR II 52 ARB telmisartan 52 tolvaptan 52 prucalopride 52 NCT# ClinicalTrials.gov 52 citalopram 52 #mg BID [003] 52 primary endpoint 52 STEALTH C 52 4mg/kg 52 genotype 1a 52 3TC lamivudine Epivir 52 everolimus eluting stent 52 Taxotere ® 52 q8h 52 intermittent dosing 52 μg dose 52 venlafaxine XR 51 angiotensin receptor blocker ARB 51 GAMMAGARD 51 RIO Lipids 51 plus prednisone 51 protease inhibitor PI 51 intravenous dose 51 Intervention Trial 51 LCP AtorFen 51 IIa trial 51 STRIDE PD 51 EFAPROXYN 51 CTA# Injection 51 ASTEROID 51 Pivotal Phase 51 3mg/kg 51 ATACAND 51 secondary efficacy endpoints 51 comparing alemtuzumab 51 bolus dose 51 REVIVE Diabetes 51 ENESTnd 51 efavirenz EFV 51 relapsing remitting MS RRMS 51 CIMZIA TM certolizumab pegol 51 mg/m2 51 TAXUS VI 51 glatiramer acetate 51 tanespimycin 51 allopurinol 51 rFVIIa 51 subcutaneous methylnaltrexone 51 evaluating carfilzomib 51 DU #b 51 randomized Phase 2b 51 PRIMO CABG 51 Phase Ib study 51 lanthanum carbonate 51 ALN VSP Phase 51 atazanavir ritonavir 51 HYVET 51 TRANSFORMS 51 #mg dose [003] 51 e HEALING 51 elotuzumab 51 Tolvaptan 51 Screening Trial 51 CURRENT OASIS 7 51 Phase IIB 51 phase Ib clinical 51 Allovectin 7 ® 51 CARE HF 51 rt PA 51 sequential dose escalation 51 RezularTM 51 subcutaneous doses 51 Phase 2b kidney transplant 51 Adalimumab 51 ABSORB trial 51 Scandinavian Simvastatin Survival 51 perampanel 51 RLAI 51 relapsing multiple sclerosis 51 Randomized Placebo Controlled 51 icatibant 51 Acute Ischemic Stroke 51 acute coronary syndromes ACS 51 ug dose 51 doxorubicin docetaxel 51 meta analysis 51 GISSI HF 51 Metabolic Efficiency 51 pertuzumab 51 VELCADE melphalan 51 Laquinimod 51 olmesartan 51 Ovarian Cancer Screening 51 EORTC 51 bosentan 51 beta2 agonist 51 pegylated interferon 51 Sequenced Treatment Alternatives 51 pain palliation 51 alvespimycin 51 paclitaxel poliglumex 51 ongoing Phase 1b 51 CIMZIA TM 51 ticagrelor 51 ARIXTRA 51 REVLIMID lenalidomide 51 dose pharmacokinetic 51 telaprevir dosed 51 intravenously administered 51 Engerix B 51 ENGAGE AF TIMI 51 headache nasopharyngitis 51 Raptiva r 51 sunitinib 51 pivotal bioequivalence 51 ORMD 51 REMINYL ® 51 MERLIN TIMI 51 FOLFIRI 51 ANCHOR trial 51 Betaferon ® 51 direct thrombin inhibitor 51 dosing 51 CYPHER ® Stent 51 Controlled Trial 51 tacrolimus ointment 51 chlorambucil 51 MabCampath 51 KAPIDEX 51 NLX P# 51 INCB# [003] 51 Lodotra TM 51 unblinding 51 irinotecan chemotherapy 51 NOXAFIL 51 lopinavir ritonavir 51 CHOP chemotherapy 51 GOUT 51 ceftazidime 51 CA4P 51 QD dosing 51 BoNTA 51 plus gemcitabine 51 Omacetaxine mepesuccinate 51 KRN# 51 median PFS 51 azilsartan medoxomil 51 Peginterferon 51 Phase III Clinical Trial 51 bortezomib Velcade R 51 ToGA 51 mGluR5 negative 51 landmark ATHENA study 51 neoadjuvant 51 lamivudine monotherapy 51 Irinotecan 51 noninferior 51 RSD# oral 51 metformin sulfonylurea 51 heFH 51 MADIT II 51 virologic 51 By JENNIFER LEARN 51 paclitaxel carboplatin 51 pramlintide 51 BAY #-# 51 evaluable subjects 51 achieved statistical significance 51 HF ACTION 51 DAPT Study 51 5 fluorouracil leucovorin 51 ATTRACT 51 randomized multicenter Phase III 51 salmeterol fluticasone 51 symptomatic VTE 51 aliskiren 51 nucleoside naive patients 51 demonstrated clinically meaningful 51 Randomized Controlled 51 acyclovir Lauriad R 51 Randomized Phase II 51 CYT# QbG# 51 antiretroviral naïve 51 refractory metastatic colorectal cancer 51 ISAR TEST 51 edoxaban 51 MAGE A3 ASCI 51 Microplasmin 51 fluticasone furoate 51 ENDEAVOR clinical 51 NICE SUGAR 51 MIVI III 50 Maximum Tolerated Dose MTD 50 tipranavir r 50 pharmacokinetic pharmacodynamic 50 liver transplant recipients 50 hemodialysis patients 50 Phase III Clinical Trials 50 μg kg 50 MIRCERA 50 efficacy tolerability 50 vastus lateralis 50 oral ibandronate 50 mg doses 50 CYPHER R Stent 50 mcg albinterferon alfa 2b 50 sirolimus eluting 50 continuous intravenous infusion 50 Liraglutide Effect 50 Aptivus ® 50 Ceplene/IL-2 50 multicenter dose escalation 50 iniparib 50 International Verapamil SR 50 cinacalcet 50 maximally tolerated dose 50 events AEs 50 Dacogen injection 50 AZILECT R 50 bupropion SR 50 Xanafide 50 ISAR REACT 50 Tyrima 50 certolizumab 50 neratinib 50 Safinamide 50 refractory CLL 50 observational cohort 50 NCCTG N# 50 Augment Injectable 50 gemcitabine 50 LibiGel Phase III 50 Multicenter Randomized Double 50 stage IIIB 50 carotid endarterectomy CEA 50 HIV HCV coinfected 50 HGS# 50 DASISION 50 tocilizumab 50 rapid virologic response 50 intra articular injection 50 SCH # 50 IFN α 50 AVOREN 50 oral COTI 50 #mg q8h 50 morphometric vertebral fractures 50 Prospective Randomized Trial 50 phase IIb III 50 Randomized Clinical Trial 50 DLTs 50 MMX mesalamine 50 PCI ExTRACT TIMI 50 pharmacodynamic PD 50 confirmatory Phase 50 oxycodone CR 50 Methylnaltrexone 50 opioid induced bowel dysfunction 50 PRESEPT 50 plus methotrexate 50 idraparinux 50 CorVue ™ 50 sitagliptin 50 YONDELIS 50 tiotropium 50 cisplatin vinorelbine 50 NSABP 50 CONQUER OB 50 trial evaluating PRX# 50 docetaxel Taxotere ® 50 Xelox 50 Phase IIa trials 50 Fibrin Pad 50 pitavastatin 50 chemoradiotherapy 50 pharmacokinetic studies 50 relapsed multiple myeloma 50 ABC/3TC 50 lomitapide 50 registrational 50 receptor tyrosine kinase inhibitor 50 Group RTOG 50 PRADAXA 50 Study Evaluating 50 LUMINATE 50 evaluating Actimmune 50 hyperphenylalaninemia HPA due 50 Intervention Effectiveness 50 rALLy clinical trial 50 forodesine 50 EmbraceAC 50 risperidone Risperdal 50 MoxDuo 50 mixed hyperlipidemia 50 mcg QD 50 multicenter trials 50 Radiation Therapy Oncology 50 Prostate Cancer Prevention 50 canakinumab 50 interferon beta 1b 50 pyridostigmine 50 demonstrated statistically significant 50 stage IIIb IV 50 ZYBRESTAT TM 50 corticosteroid dose 50 5mg/kg 50 AERAS-#/Crucell Ad# 50 INCB# [001] 50 PICSO ® 50 deferiprone 50 Phase IIA 50 mg qd 50 AEGR 50 FOLPI 50 temozolomide 50 Pharmacokinetic 50 peg IFN 50 CUSTOM II 50 RE LY trial 50 tipranavir 50 CCX# B 50 plus Copegus R 50 pharmacokinetic profile 50 factor Xa inhibitor 50 clinical pharmacology studies 50 Betaferon R 50 IBS C 50 5-FU/LV 50 TYKERB 50 Monotherapy 50 ACE inhibitor ramipril 50 oral allopurinol 50 CAELYX 50 ibandronate 50 biliary tract cancer 50 XIENCE V Stent System 50 investigational protease inhibitor 50 piperacillin tazobactam 50 Dose Ranging Study 50 olmesartan medoxomil 50 EOquin TM 50 nitazoxanide 50 eplerenone 50 rilpivirine 50 Communities ARIC study 50 #mg/kg [002] 50 naltrexone SR 50 subcutaneous dose 50 Pharmacokinetic Study 50 safinamide 50 octreotide LAR 50 ganetespib 50 Matrix Phase 2b 50 #mg/m# [002] 50 CYPHER Stent 50 SEROQUEL 50 low dose cytarabine 50 migraine prophylaxis 50 prospective longitudinal 50 REBETOL 50 Blinatumomab 50 bevacizumab Avastin 50 OZURDEX ® 50 doxorubicin cyclophosphamide 50 Randomized placebo controlled 50 PROMACTA 50 mg subcutaneous injection 50 PROTEGE 50 INTEGRILIN R 50 ADAGIO study 50 sorafenib tablets 50 VNP#M 50 FOLFOX6 chemotherapy regimen 50 miconazole Lauriad ® 50 standard chemotherapy regimen 50 TORISEL 50 thymalfasin 50 tapentadol ER 50 ONTARGET R 50 AVADO 50 CLARITY TIMI 50 SIMPADICO 50 VELCADE 49 RADIANT 49 placebo dexamethasone 49 catheter occlusion 49 number NCT# ClinicalTrials.gov 49 oral FTY# 49 abciximab 49 MoxDuo IR 49 trials BLISS 49 chemotherapy FOLFOX 49 Fludara 49 Afatinib 49 ragweed allergic 49 trastuzumab Herceptin R 49 TELCYTA 49 Arimidex Tamoxifen Alone 49 MEND CABG II 49 aspirin clopidogrel 49 HZT 49 inhalations twice 49 ACCOMPLISH 49 dexpramipexole 49 mg kg dose 49 coronary intervention 49 eosinophilic asthma 49 lenalidomide dexamethasone 49 SUCCEED trial 49 Diabetic Macular Edema DME 49 maximal dose 49 stable angina pectoris 49 European Sepsis Trial 49 MSI #F 49 vinorelbine 49 trabectedin 49 Left Ventricular Dysfunction 49 tenofovir emtricitabine 49 dosing schedules 49 fluvastatin 49 Taxus Stent 49 recurrent GBM 49 #mg/m# [001] 49 dirucotide MBP# 49 CML CP 49 Acute Coronary Syndromes ACS 49 induced macular edema 49 IMPROVE IT 49 SORT OUT III 49 oral prodrug 49 coadministration 49 CORD II 49 randomisation 49 Sapacitabine 49 Torisel 49 intravenous IV infusion 49 #mg QD [001] 49 ARCOXIA 49 EXPLORE Xa 49 ELONVA 49 nulliparous women 49 saline placebo 49 liposome injection 49 MGd 49 Phase III clinical trials 49 alpha 2a 49 etanercept 49 Ranolazine 49 fostamatinib 49 BENICAR 49 amlodipine 49 INSPIRE Trial Phase III 49 CR nPR 49 Pivotal Phase III 49 HORIZONS AMI trial 49 EVIZON 49 fistulizing Crohn disease 49 lixisenatide 49 PARTNER Trial 49 q#h 49 MoxDuo TM IR 49 IIIa inhibitor 49 primary efficacy endpoint 49 VITAL Trial 49 DP b# 49 COPAXONE R 49 unfractionated heparin 49 paricalcitol 49 undergoing elective percutaneous 49 non splenectomized 49 unstable angina UA 49 WHIMS 49 Linagliptin 49 CALGB # [001] 49 liposomal formulation 49 acute PAO 49 DIRECT Trial 49 Elagolix 49 deforolimus 49 HCD# [002] 49 Aflibercept 49 bevacizumab 49 Contrave# 49 definite stent thrombosis 49 FOSRENOL R 49 #mg doses [002] 49 ELACYT 49 hypertensive patients 49 PEG IFN 49 XIENCE V Everolimus Eluting 49 Elacytarabine 49 IMPROVE HF 49 Protelos 49 Fondaparinux 49 clopidogrel 49 Multi Ethnic Study 49 SANTE 49 KRAS mutations occur 49 neurologic progression 49 Autologous Stem Cell Transplantation 49 inhaled corticosteroid ICS 49 Imprime PGG 49 LEXIVA 49 efficacy endpoint 49 CIMZIA ™